Skip to main content
. 2015 Jun 11;11(8):970–981. doi: 10.7150/ijbs.11635

Figure 6.

Figure 6

DT-13 supressed ICAM-1 and VCAM-1 expression in vivo. (A-B). DT-13 inhibited ICAM-1 (A) or VCAM-1 (B) expression in aortic endothelial cells activated by TNF-α. ICAM-1 or VCAM-1 was labeled using anti-ICAM-1 or anti-VCAM-1 antibodies (FITC-labeled secondary antibodies, 488 nm) and anti-CD31 (TRITC- FITC-labeled secondary antibody, 594 nm). The arrow denotes ICAM-1 and VCAM-1 on ECs. Bar=100 μm. The data are represented as the mean ± SD of five areas of one aorta. (C-D). DT-13 decreased serum concentrations of sICAM-1 (C) or sVCAM-1 (D) in TNF-α- treated mice by an ELISA assay. ##P<0.01 νs. the control group; * P<0.05, ** P<0.01 νs. the TNF-α group.